Loading...

Cellectis S.A.

CLLS•NASDAQ
Healthcare
Biotechnology
$2.00
$-0.33(-14.16%)

Cellectis S.A. (CLLS) Stock Overview

Explore Cellectis S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.5/100

Key Financials

Market Cap192M
P/E Ratio-3.37
EPS (TTM)$-0.67
ROE-0.46%
Fundamental Analysis

AI Price Forecasts

1 Week$1.42
1 Month$0.66
3 Months$2.06
1 Year Target$0.78

CLLS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cellectis S.A. (CLLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 58.19, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.78.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.37 and a market capitalization of 192M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;